Endothelin-1 reduces the ability of insulin to promote glucose uptake into cells by interfering with the cytoskeletal changes that move GLUT4 transporters to the cell surface.
See the scientific wording
Endothelin-1 inhibits insulin-stimulated glucose uptake by disrupting RAC1-mediated cytoskeletal remodeling required for GLUT4 translocation.
There's disagreement
ObservationalThe 3 studies we reviewed point in different directions — there's no clear consensus.
What the research says
3 studies reviewedSupporting (2)
Endothelin-1 inhibits insulin-stimulated glucose uptake in isolated rat adipocytes.
Case-Control StudyAnimal1994
This study shows that a substance called endothelin-1 blocks insulin from helping cells take in sugar, even though insulin itself still works fine. This supports the idea that endothelin-1 interferes with the cell’s internal machinery needed to move sugar transporters to the surface.
Endothelin‐1 impairs glucose transporter trafficking via a membrane‐based mechanism
Cross-Sectional StudyIn vitro2006
Endothelin-1 messes up the cell’s internal scaffolding needed to move glucose transporters to the surface, so insulin can’t do its job. The study shows this happens by breaking down key building blocks in the cell’s structure.
Contradicting (1)
Case-Control StudyAnimal
The study shows that endothelin-1 makes it harder for insulin to get sugar into fat cells, but it doesn’t explain how—so we don’t know if it’s because of the cytoskeleton or something else.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Endothelin-1 binds to receptors on the cell surface, triggering a signal that breaks down the internal scaffold made of actin and membrane lipids needed to move glucose transporters to the surface. Without this scaffold, the transporters cannot reach the membrane, so glucose cannot enter the cell even when insulin is present.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 2 supporting, 1 contradicting studies
Related videos
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
Endothelin-1 reduces the ability of insulin to promote glucose uptake into cells by interfering with the cytoskeletal changes that move GLUT4 transporters to the cell surface.
Mechanism
5 studiesEndothelin-1 locks glucose transporters inside the cell by breaking down the internal scaffold they need to reach the surface. Even when insulin signals for sugar to enter, the transporters can't move without this scaffold, so glucose stays outside.
Endothelin-1 binds to receptors on the cell surface, triggering a signal that breaks down the internal scaffold made of actin and membrane lipids needed to move glucose transporters to the surface. Without this scaffold, the transporters cannot reach the membrane, so glucose cannot enter the cell even when insulin is present.
Endothelin-1 binds to ETA receptors on the plasma membrane
ETA receptor activation initiates a membrane-proximal signaling cascade that does not require intracellular calcium or PKC
Signaling reduces plasma membrane phosphatidylinositol 4,5-bisphosphate (PIP2) and destabilizes cortical actin filaments
Disruption of PIP2 and actin impairs cytoskeletal remodeling required for GLUT4 vesicle trafficking and fusion with the plasma membrane
GLUT4 transporters remain trapped in intracellular vesicles and fail to translocate to the cell surface
Reduced surface GLUT4 prevents insulin-stimulated glucose uptake
Evidence from Studies
Last searched 3mo ago
Supporting (2)
Community contributions welcome
Endothelin-1 inhibits insulin-stimulated glucose uptake in isolated rat adipocytes.
This study shows that a substance called endothelin-1 blocks insulin from helping cells take in sugar, even though insulin itself still works fine. This supports the idea that endothelin-1 interferes with the cell’s internal machinery needed to move sugar transporters to the surface.
Endothelin‐1 impairs glucose transporter trafficking via a membrane‐based mechanism
Endothelin-1 messes up the cell’s internal scaffolding needed to move glucose transporters to the surface, so insulin can’t do its job. The study shows this happens by breaking down key building blocks in the cell’s structure.
Contradicting (1)
Community contributions welcome
The study shows that endothelin-1 makes it harder for insulin to get sugar into fat cells, but it doesn’t explain how—so we don’t know if it’s because of the cytoskeleton or something else.
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
Clinical support requires direct evidence. Mechanistic proxy and tangential studies contribute only to the mechanistic score.
- All linked studies are tangential or mechanistic proxies — no direct test of the claim has been found.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review of Endothelin-1 Effects on Insulin-Mediated Glucose Uptake in Human and Animal Models
Systematic review and meta-analysis of all published controlled studies measuring glucose uptake in response to insulin with and without endothelin-1 exposure, stratified by model system and RAC1/GLUT4 pathway markers.
Double-Blind Placebo-Controlled Trial of Endothelin-1 Blockade on Insulin-Stimulated Glucose Uptake in Human Skeletal Muscle
Randomized, double-blind, placebo-controlled trial in insulin-resistant adults comparing endothelin receptor antagonist versus placebo, measuring insulin-stimulated glucose disposal via hyperinsulinemic-euglycemic clamp and GLUT4 translocation in muscle biopsies over 4 weeks.
Prospective Cohort Study of Circulating Endothelin-1 Levels and Insulin Sensitivity in a General Population Over 5 Years
Prospective cohort of 5,000 adults with baseline plasma endothelin-1 measurements, followed for 5 years with annual assessments of insulin sensitivity (HOMA-IR, clamp), and adjustment for BMI, age, and inflammation markers.
In Vitro Study of Endothelin-1 on RAC1 Activation and GLUT4 Translocation in Human Skeletal Muscle Cells
Primary human skeletal muscle myotubes treated with insulin ± endothelin-1, with RAC1 activation measured by G-LISA, cytoskeletal dynamics via live-cell imaging, and GLUT4 translocation via fluorescent tagging and membrane fractionation over 30–120 minutes.
Mouse Model Study of Endothelin-1 Knockdown on Insulin-Stimulated Glucose Uptake and RAC1-GLUT4 Dynamics in Muscle Tissue
C57BL/6 mice with inducible endothelin-1 knockdown in skeletal muscle, compared to controls, under high-fat diet conditions; glucose uptake measured by 2-DG tracer, RAC1 activity by pulldown, GLUT4 translocation by immunofluorescence in muscle sections after insulin challenge over 8 weeks.